2023
Risk of Squamous Cell Carcinoma of the Breast Following Postmastectomy Implant Reconstruction in Women With Breast Cancer and Carcinoma in Situ
Kinslow C, Yu J, DeStephano D, Kachnic L, Cheng S, Neugut A, Horowitz D. Risk of Squamous Cell Carcinoma of the Breast Following Postmastectomy Implant Reconstruction in Women With Breast Cancer and Carcinoma in Situ. JAMA Surgery 2023, 158: 769-771. PMID: 37074722, PMCID: PMC10116379, DOI: 10.1001/jamasurg.2023.0262.Peer-Reviewed Original ResearchMeSH KeywordsBreastBreast ImplantsBreast NeoplasmsCarcinoma in SituCarcinoma, Squamous CellFemaleHumansMammaplastyMastectomy
2020
Physician trajectories of abandoning long‐course breast radiotherapy and their cost impact
Xu X, Soulos PR, Herrin J, Wang S, Pollack CE, Evans SB, Yu JB, Gross CP. Physician trajectories of abandoning long‐course breast radiotherapy and their cost impact. Health Services Research 2020, 56: 497-506. PMID: 33070305, PMCID: PMC8143683, DOI: 10.1111/1475-6773.13572.Peer-Reviewed Original ResearchConceptsPhysician peer groupsWhole breast irradiationCF-WBIRisk-adjusted ratesBreast radiotherapyPractice patternsLow useChronic Conditions Data WarehouseDistinct practice patternsPatients' clinical characteristicsSetting of radiotherapyAdjuvant breast radiotherapyYears of ageDistinct trajectoriesImportant cost implicationsHigher useAdjuvant radiotherapyClinical characteristicsEligible womenBreast cancerCost implicationsLatent class growth analysisService beneficiariesMedicare programRadiotherapyBeyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today
Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, Lee J, Kirkpatrick JP, Breen W, Brown PD, Shi D, Shih HA, Soliman H, Sahgal A, Shanley R, Sperduto W, Lou E, Everett A, Boggs DH, Masucci L, Roberge D, Remick J, Plichta K, Buatti JM, Jain S, Gaspar LE, Wu CC, Wang TJC, Bryant J, Chuong M, Yu J, Chiang V, Nakano T, Aoyama H, Mehta MP. Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. International Journal Of Radiation Oncology • Biology • Physics 2020, 107: 334-343. PMID: 32084525, PMCID: PMC7276246, DOI: 10.1016/j.ijrobp.2020.01.051.Peer-Reviewed Original ResearchConceptsDiagnosis-specific prognostic factorsHuman epidermal receptor 2Prognostic factorsMedian survivalBreast-GPABrain metastasesBreast cancerCohort BCohort APrognostic indexReceptor 2Tumor subtypesBreast cancer brain metastasesKaplan-Meier survival estimatesCancer brain metastasesGraded Prognostic AssessmentKarnofsky performance statusLarge contemporary cohortLog-rank testFuture clinical trialsNew prognostic factorsGPA 0Extracranial metastasesPerformance statusBetter prognosisEstrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival
Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, Lee J, Kirkpatrick JP, Breen W, Brown PD, Shi D, Shih HA, Soliman H, Sahgal A, Shanley R, Sperduto W, Lou E, Everett A, Boggs DH, Masucci L, Roberge D, Remick J, Plichta K, Buatti JM, Jain S, Gaspar LE, Wu CC, Wang TJC, Bryant J, Chuong M, Yu J, Chiang V, Nakano T, Aoyama H, Mehta MP. Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. Neuro-Oncology 2020, 22: 1359-1367. PMID: 32034917, PMCID: PMC7523450, DOI: 10.1093/neuonc/noaa025.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBrain NeoplasmsBreast NeoplasmsEstrogensHumansReceptor, ErbB-2Receptors, ProgesteroneRetrospective StudiesConceptsBreast cancer brain metastasesHuman epidermal growth factor receptor 2Primary tumorProgesterone receptorMedian survivalEstrogen receptorBrain metastasesDiscordance rateHER2-negative primary tumorsEstrogen/progesterone receptorsEpidermal growth factor receptor 2Time of metastasisCancer brain metastasesGrowth factor receptor 2Breast cancer treatmentIncidence of discordanceFactor receptor 2Subsequent treatmentBCBM patientsHER2 discordanceReceptor discordanceMost patientsReceptor statusInitial diagnosisHER2 status
2019
Income disparities in needle biopsy patients prior to breast cancer surgery across physician peer groups
Killelea BK, Herrin J, Soulos PR, Pollack CE, Forman HP, Yu J, Xu X, Tannenbaum S, Wang SY, Gross CP. Income disparities in needle biopsy patients prior to breast cancer surgery across physician peer groups. Breast Cancer 2019, 27: 381-388. PMID: 31792804, PMCID: PMC7512133, DOI: 10.1007/s12282-019-01028-4.Peer-Reviewed Original ResearchConceptsPhysician peer groupsLow-income patientsNeedle biopsyOdds ratioHigh-income patientsBreast cancer surgeryMethodsThe SurveillanceCancer surgeryIncome patientsMedicare databaseBiopsy patientsMedicare beneficiariesPatientsBiopsyLow incomeGroupDisparitiesReceiptEnd resultHigher incomeSurgeryPeer groupEpidemiologyFurther workGroup-level effects
2018
Medicare Cancer Screening in the Context of Clinical Guidelines
Maroongroge S, Yu J. Medicare Cancer Screening in the Context of Clinical Guidelines. American Journal Of Clinical Oncology 2018, 41: 339-347. PMID: 26886947, DOI: 10.1097/coc.0000000000000272.Peer-Reviewed Original ResearchConceptsCancer screeningScreening ratesFee-for-serviceColorectal cancer screening ratesBilling codesCancer screening ratesColorectal screening testsMedicare fee-for-serviceMedicare Part B beneficiariesMonte Carlo permutation methodMedicare FFS populationBeneficiaries per yearMedicare FFS programEvidence-based guidelinesScreening testRetrospective claims dataProstate cancer screeningPublic health issueMammography ratesFFS populationScreening trendsMedicare populationClaims dataGuideline publicationPatient preferences
2017
Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study
Kaidar-Person O, Meattini I, Jain P, Bult P, Simone N, Kindts I, Steffens R, Weltens C, Navarria P, Belkacemi Y, Lopez-Guerra J, Livi L, Baumert B, Vieites B, Limon D, Kurman N, Ko K, Yu J, Chiang V, Poortmans P, Zagar T. Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study. Breast Cancer Research And Treatment 2017, 167: 479-483. PMID: 28975433, DOI: 10.1007/s10549-017-4526-8.Peer-Reviewed Original ResearchConceptsBreast cancer patientsSubsequent brain metastasesHuman epidermal growth factor receptor 2Brain metastasesCancer patientsEthical research committeeReceptor statusPrimary tumorProgesterone receptorEstrogen receptorEpidermal growth factor receptor 2Triple-negative profileGrowth factor receptor 2Primary breast cancerPrimary breast tumorsInternational multicenter studyFactor receptor 2Multicenter studyAvailable histologyResultsA totalBreast cancerReceptor 2ConclusionsThe majorityPatientsBreast tumors
2016
Radiation Oncology Practice: Adjusting to a New Reimbursement Model.
Konski A, Yu J, Freedman G, Harrison L, Johnstone P. Radiation Oncology Practice: Adjusting to a New Reimbursement Model. JCO Oncology Practice 2016, 12: e576-83. PMID: 27006359, DOI: 10.1200/jop.2015.007385.Peer-Reviewed Original ResearchConceptsRelative value unitsRadiation oncologyTechnical revenueFee-for-service modelDeliver hypofractionated radiotherapyValue-based environmentRadiation oncology departmentsFee-for-serviceLung cancer casesHypofractionated radiotherapyHypofractionation usePalliative treatmentHypofractionationCancer casesPatient volumeLung cancerReimbursement modelsStaff timeOncology departmentValue unitsIncreasing skillsStaffProstateWorkforce predictionsPatients
2014
Breast cancer brain metastases: one step at a time.
Yu J. Breast cancer brain metastases: one step at a time. Oncology 2014, 28: 570. PMID: 25144275.Peer-Reviewed Original Research